Effect of Cytotoxic Cells on Minimal Residual Leukemia

References

• Bortin M., Horowitz M., Gale R. Current status of bone marrow transplantation in humans. Nat Imm cell Growth Reg. 1988; 7: 334–350
   PubMedGoogle Scholar
• Butturini A., Gale R. P. How can we cure leukemia?. Br J Haematol. 1989; 72: 479–485
   PubMed Web of Science ®Google Scholar
• Slavin S., Eckerstein A., Weiss L. Adoptive immunotherapy in conjunction with bone marrow transplantation-amplification of natural host defence mechanisms against cancer by recombinant IL-2. Nat Immun Cell Growth Regul. 1988; 7: 180–184
   PubMedGoogle Scholar
• Cramer D. V., Long G. S. Elimination of leukemia cells from normal bone marrow with lymphokine activated killer cells. Nat Imm Cell Growth Regul. 1988; 7: 34–53
   Google Scholar
• Reittie J. E., Gottlieb D., Heslop H. E., Leger O., Drexler H. G., Hazlehurst G., Hoffbrand A. V., Prentice H. G., Brenner M. K. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Abstr Brit Soc Hematol 1989; 22
   Google Scholar
• Hercend T., Schmidt R. E. Characteristics and uses of natural killer cells. Immunology Today. 1988; 9: 291–293
   PubMedGoogle Scholar
• Timonen T., Ortaldo J. R., Herberman R. B. Characteristics of human lerge granular lymphocytes and relationship to natural killer and K cells. J Exp Med. 1981; 153: 569–582
   PubMed Web of Science ®Google Scholar
• Triebel F., Hercend T. Subpopulations of human killer lymphocytes with potential antitumor activity. Nat Imm Cell Growth Regul. 1988; 7: 34
   Google Scholar
• Loughran T. P., Starkebaum G., Aprile J. A. Rearrangement and expression of T-cell receptor genes in large granular lymphocyte leukemia. Blood. 1988; 71: 822–824
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A. Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. Important Adv. Oncology. 1986; 55–91
   PubMedGoogle Scholar
• Kasid A., Morecki S., Aebersold P., Cornetta K., Culver K., Director P., Lotze M., Blaese M., Andersson W. F., Rosenberg S. A. Characterization of human tumor infiltrating lymphocytes (TIL) and their possible use for targeting exogenous genetic material into man. Proc VII Congr Immunol. Berlin 1989; 124–13
   Google Scholar
• Whiteside T., Heo D. S., Takagi S., Jonhson J. T., Iwatsuki S., Herberman R. B. Cytolytic antitumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes in recombinant interleukin-2. Cancer Immunol Immu-nother. 1988; 26: 1–10
   PubMed Web of Science ®Google Scholar
• Anderson T. M., Ibayashi Y., Tokuda Y., Colquhoun S. D., Holmes E. C., Golub S. H. Effects of systemic recombinant Interleukin-2 on natural killer and lymphokine activated killer activity of human tumor-infiltrating lymphocytes. Cancer Res. 1988; 48: 1180–1183
   PubMed Web of Science ®Google Scholar
• Ferradini L., Miesher S., Busson P., Barras C., Lipinsky M., von Fliedn V., Tursch T. Cytotoxic tumor infiltrating lymphocytes in nasopharyngeal carcinoma. Proc VII Congr Immunol. Berlin 1989; 100–16
   Google Scholar
• Herbermann R. B., Melder R. J., Schwartz R. E., Elder E. M., Whiteside T. Biologic properties and antitumor function of human adherent lymphokine activated killer (A-LAK) cells. Proc VII Congr Immunol. Berlin 1989; 100–30
   Google Scholar
• LeFor A. T., Eisenthal A., Rosenberg S. A. Heterogeneity of lymphokine activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts and modified syngeneic blasts. J Immunol. 1988; 140: 4062–4069
   PubMed Web of Science ®Google Scholar
• Kawase I., Komuta K., Hara H., Inoue T., Hosoe S., Ikeda T., Shirasaka T., Yokota S., Tanio Y., Masuno T., Kishimoto S. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity. Cancer Res. 1988; 48: 1173–1179
   PubMed Web of Science ®Google Scholar
• Oshimi K., Oshimi Y., Saito H., Mizoguchi H. Cytotoxicity of interleukin-2 activated lymphocytes for autologous normal blood mononuclear cells. J Immunol Methods. 1988; 109: 161–168
   PubMed Web of Science ®Google Scholar
• Panayotides P., Porwit A., Sjögren A. M., Wasserman J., Reizenstein P. Resistance of some leukemic blasts to lysis by lymphokine activated killer (LAK) cells. Eur J Hematol. 1988; 40: 362–367
   PubMed Web of Science ®Google Scholar
• Vasilopuolos G., Sjögren A. M., Reizenstein P. Cytotoxic effect on viable human leukemic cells by combinations of lymphokine activated killer cells and monoclonal antibodies. Leukemia Res. 1989; 13: 87–91
   PubMed Web of Science ®Google Scholar
• Fierro M. T., Liao X. S., Lusso P., Bonferroni M., Matera L., Cesano A., Lista P., Arione R., Forni G., Foa R. In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity. Leukemia. 1988; 2: 50–54
   PubMed Web of Science ®Google Scholar
• Lotzova E., Savary C. A., Herberman R. B. Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors. Leukemia Res. 1987; 11: 1059–1066
   PubMed Web of Science ®Google Scholar
• Takahashi M., Oshimi K., Saito H., Mizoguchi H. Inhibition of human granulocyte-macrophage colony formation by interleukin 2-treated lymphocytes. Exp Hemat. 1988; 16: 226–230
   PubMed Web of Science ®Google Scholar
• Nagler A., Lanier L. L., Philips J. H. Fc receptor positive and negative subpopulations of natural killer cells. Proc VII Congr Immunol. Berlin. 1989; 100–52
   Google Scholar
• Fujimori Y., Hara H., Nagai K. Effect of lymphokine activated killer cell fraction on the development of human hematopoietic progenitor cells. Cancer Res. 1987; 48: 534–538
   Web of Science ®Google Scholar
• Stevenson H. C., Stevenson G. W., Lacerna L. V. J. R. The treatment of cancer with activated cytotoxic leukocyte subsets. Art Organs. 1988; 12: 128–136
   PubMed Web of Science ®Google Scholar
• Young J. D. E., Liu C. C. Multiple mechanisms of lymphocyte-mediated killing. Immunology Today. 1988; 9: 140–144
   PubMedGoogle Scholar
• Maghazachi A. A., Herbermann R. B., Vujanovic N. L., Hiserodt J. C. In vivo distribution and tissue localization of highly purified rat lymphokine-activated killer (LAK) cells. Cell Immunol. 1988; 115: 179–194
   PubMed Web of Science ®Google Scholar
• McCrady C. W., Li F., Grant A. J., Merchant R. E., Carchman R. A. Alteration of human lymphokine-activated killer activity by manipulation of protein kinase C and cytosolic Ca2 +. Cancer Res. 1988; 48: 635–640
   PubMed Web of Science ®Google Scholar
• Frey J. R., Kamber M., Peck R. Recombinant interferons or interleukin-2 increase cytotoxicity by human monocytes and NK cells. Lymphokine Res. 1987; 6: 215–227
   PubMedGoogle Scholar
• Bergmann L., Weidemann E., Bungert B., Mitrou P. S. Promotion of LAK induction with combination of cytokines. Proc VII Congr Immunol. Berlin 1989; 100–6
   Google Scholar
• Eggermont A. M. M., Sugarbaker P. H., Marqet R. L., Jeekel J. In vivo generation of lymphokine activated killer cell activity by ABPP and interleukin-2 and their antitumor effect against immunogenic and nonimmunogenic tumors in murine tumor model. Cancer Immunol Immunother. 1988; 26: 23–30
   PubMed Web of Science ®Google Scholar
• Axberg I. (Karolinska Inst) Studies of natural killer cells in rodents and man. Dissertation. Stockholm 1989.
   Google Scholar
• Weiner L. M., Ring D. Enhancement of in vitro human LAK cell activity by tumor binding monoclonal antibodies. Proc Ann Meet Am Assoc Ca Res. 1987; 28: 363
   Web of Science ®Google Scholar
• Grimm E. A., Crump W. L., Durett A., Hester J. P., Lagoo-Deenadalayan S., Owen-Schaub L. B. TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity. Cancer Immunol Immunother. 1988; 26: 53–58
   Google Scholar
• Jin B., Lopez A. F., Gillis S., Juttner C., Vadas M. A., Burn G. F. Human Interleukin-4 regulates the phenotype of lymphocytes generated during mixed lymphocyte culture and inhibits the IL-2 induced development of LAK function in normal and leukemic cells. Leukemia Res. 1989; 13: 297–305
   PubMed Web of Science ®Google Scholar
• Baldwin R. W., Embleton M. J. Assessment of cell-mediated immunity to human tumor associated antigens. Int Rev Exp Pathol. 1977; 17: 49–95
   PubMedGoogle Scholar
• McMannis J. D., Fisher R. I., Creekmore S. P., Braun D. P., Harris J. E., Ellis T. M. In vivo effects of recombinant IL-2.I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2. J Immunol. 1988; 140: 1335–1340
   PubMed Web of Science ®Google Scholar
• Pulley M. S., Dumonde D. C. The therapeutic potential of lymphokines in neoplastic disease. Ann NY Acad Sci 1988; 274–289
   PubMed Web of Science ®Google Scholar
• Lafreniere R., Rosenberg S. A. Successful immunotherapy of murine experimental hepatic metastases with lymphokine activated killer cells and recombinant interleukine 2. Cancer Res. 1985; 45: 3735–3741
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Lotze M., Muul L. M. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Eng J Med. 1987; 316: 889–897
   PubMed Web of Science ®Google Scholar
• West W. H., Tower K. W., Yanelli J. R., Marshall G. D., Orr D. W., Thurman G. B., Oldham R. K. Constant infusion of recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Eng J Med. 1987; 316: 898–905
   PubMed Web of Science ®Google Scholar
• Shau H., Gray J. D., Mitchell M. S. Studies on the relationship of human natural killer and lymphokine-activated killer cells with lysosomal staining and analysis of surface marker phenotypes. Cell Immunol. 1988; 115: 13–23
   PubMed Web of Science ®Google Scholar
• Sawada H., Abo T., Sugawara S., Kumagai K. Prerequisite for the induction of lymphokine-activated killer cells from T lymphocytes. J Immunol. 1988; 140: 3668–3673
   PubMed Web of Science ®Google Scholar
• Michon J. M., Caligiuri M. A., Hazanow S. M., Levine H., Schlossman S. F., Ritz J. Induction of natural killer eels from human thumus with recombinant IL-2. J Immunol. 1988; 140: 3660–3667
   PubMed Web of Science ®Google Scholar
• Tahara T., Iseki R., Morishima Y., Yokomaku S., Ohno R., Saito H. Generation and characterization of lymphokine-activated killer cells against fresh human leukemia cells. Jpn J Cancer Res. 1988; 79: 390–399
   PubMedGoogle Scholar
• Adler A., Chervenick P. A., Whiteside T. L., Lotzov E., Herbermann R. B. Interleukin 2 induction of lymphokine-activated. (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood. 1988; 71: 709–716
   PubMed Web of Science ®Google Scholar
• Boldt D. H., Mills B. J., Gemlo B. T., Holden H., Mier J., Paietta E., McMannis J. D., Escobedo L. V., Sniecinski I., Rayner A. A., Hawkins M. J., Atkins M. B., Ciobanu N., Ellis T. M. Laboratory correlates of adoptive immunotherapy with recombinant Interleukin-2 and lymphokine activated killer cells in humans. Cancer Res. 1988; 48: 4409–4416
   PubMed Web of Science ®Google Scholar